Predicted to enable several functions, including G protein-coupled receptor activity; Hsp70 protein binding activity; and PDZ domain binding activity. Predicted to be involved in several processes, including G protein-coupled receptor signaling pathway; cellular response to reactive oxygen species; and dendrite development. Predicted to act upstream of or within dopamine biosynthetic process; locomotion involved in locomotory behavior; and positive regulation of dopamine metabolic process. Predicted to be located in endoplasmic reticulum. Predicted to be part of receptor complex and ubiquitin ligase complex. Predicted to be active in cell surface; plasma membrane; and synapse. Orthologous to human GPR37 (G protein-coupled receptor 37); PARTICIPATES IN Parkinson's disease pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; ammonium chloride.
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA